Ultragenyx Pharmaceutical's GAAP loss for 3 months of 2022 was $152.32 million, up 11.9% from $136.141 million in the previous year. Revenue decreased 19.6% to $79.935 million from $99.395 million a year earlier.

Ultragenyx Pharmaceutical's GAAP loss for 2021 was $454.025 million, up 2.4 times from $186.566 million in the previous year. Revenue increased 29.7% to $351.406 million from $271.03 million a year earlier.

Ultragenyx Pharmaceutical's GAAP loss for 9M 2021 was $331.567 million, having doubled from $162.555 million in the previous year. Revenue increased by 49.3% to $268.017 million compared to $179.488 million a year earlier.

Loss of Ultragenyx Pharmaceutical on GAAP for 6 months of 2021 amounted to $258.569 million, increasing 2.8 times compared to $93.71 million in the previous year. Revenue increased 90.1% to $186.37 million from $98.018 million a year earlier.